Trial Profile
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ISABR Study
- 06 Jul 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 06 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 01 Jul 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.